Recently, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes.
Jardiance is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of death and hospitalization in patients with heart failure and low ejection fraction.
Heart failure is a syndrome in which the heart is not meeting the needs of the body, affecting more than 650,000 people in the U.S. each year.
Despite therapies in multiple drug classes, mortality remains high and treatment options for a broader range of patients are needed.
Symptoms of heart failure vary but can include shortness of breath, fatigue, and swelling in the legs. Heart failure becomes more common with age and is the leading cause of hospitalization in people over 65 years old.
For approval, Jardiance’s safety and effectiveness were evaluated as an adjunct to standard of care therapy in a randomized, double-blind, international trial comparing 2,997 participants who received Jardiance, 10 mg, once daily to 2,991 participants who received the placebo.
The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure.
Of the individuals who received Jardiance for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the placebo.
This benefit was mostly attributable to fewer patients being hospitalized for heart failure.
The side effects in clinical studies with Jardiance for patients with heart failure were generally consistent with side effects for patients with diabetes.
In diabetic patients, the most common adverse events were urinary tract infections and female fungal infections.
Jardiance must not be used in patients who previously have had a serious allergic reaction to it as well as patients on dialysis.
The FDA granted the approval of Jardiance to Boehringer Ingelheim.
If you care about heart failure, please read studies about diabetes drug that could revolutionize heart failure treatment, and this drug can be a low-cost heart failure treatment
For more information about heart health, please see recent studies about small surgery that can prevent strokes in people with heart issues, and results showing this drug combo can cut risk of stroke and heart attack by half.
